Executive Order Targets Accelerated Development and Access Pathways for Psychedelic Therapies in Mental Health

Key Takeaways 

• A new executive order directs federal agencies to accelerate the development, review, and potential access pathways for investigational psychedelic therapies targeting serious mental illness. 
• The policy includes regulatory, research, and funding initiatives, including priority review mechanisms, expanded clinical trial efforts, and coordination across federal agencies. 
• The action signals growing federal interest in emerging mental health treatments while raising important regulatory, evidentiary, and controlled substance scheduling considerations. 

A new executive order issued April 18, 2026, outlines a series of federal actions aimed at accelerating the development and potential access to investigational psychedelic therapies for patients with serious mental illness, reflecting increasing policy attention to emerging treatment modalities in behavioral health.

The order directs multiple federal agencies—including the US Food and Drug Administration (FDA), the Department of Health and Human Services (HHS), and the Drug Enforcement Administration (DEA)—to take coordinated steps to reduce regulatory barriers, expand research, and facilitate earlier access pathways for certain investigational products.

FDA Priority Review and Breakthrough Therapy Alignment

A central component of the order is the directive for the FDA to apply Commissioner’s National Priority Vouchers to eligible psychedelic drug candidates that have received Breakthrough Therapy designation for serious mental illnesses.

This approach is intended to expedite regulatory review timelines while maintaining existing evidentiary standards for safety and efficacy. Breakthrough Therapy designation is typically granted to investigational therapies that show preliminary clinical evidence of substantial improvement over available treatments, and its application to psychedelic compounds reflects growing clinical interest in this category.

The use of priority vouchers in this context may signal a broader policy effort to align expedited regulatory pathways with areas of high unmet medical need, including treatment-resistant psychiatric conditions.

Expanded Access Through Right to Try Framework

The order also directs the FDA and DEA to establish a pathway for eligible patients to access certain investigational psychedelic therapies under the Right to Try Act, provided that basic safety criteria have been met and the products are under FDA review.

This provision could expand access outside traditional clinical trial settings, particularly for patients with serious or treatment-resistant conditions. However, it also raises considerations regarding the following:

• Patient selection and eligibility criteria
• Oversight of investigational product use outside clinical trials
• Data collection and safety monitoring

The intersection of controlled substance regulation and expanded access pathways may require additional guidance from both FDA and DEA.

Federal Investment in Research and Evidence Generation

The executive order calls for $50 million in federal funding through the Advanced Research Projects for Health (ARPA-H) to support research into psychedelic therapies, with an emphasis on matching state-level investments.

In addition, HHS and FDA are directed to collaborate with the US Department of Veterans Affairs and private sector stakeholders to increase clinical trial participation and evidence generation.

These provisions underscore a continued emphasis on building a robust clinical evidence base, which remains a key requirement for regulatory approval and broader adoption of novel therapies.

Controlled Substance Scheduling Considerations

Recognizing the regulatory complexity associated with psychedelic compounds, the order instructs the Attorney General to initiate rescheduling reviews following successful completion of phase 3 clinical trials, where appropriate.

This step is critical, as many psychedelic substances are currently classified under Schedule I of the Controlled Substances Act, which imposes significant restrictions on research, prescribing, and commercialization.

The directive suggests an effort to align drug scheduling decisions more closely with clinical evidence and FDA approval timelines, though the rescheduling process remains subject to statutory and administrative requirements.

Broader Policy Context and Implications

The executive order reflects a broader federal focus on addressing unmet needs in serious mental illness, particularly for populations such as military veterans, where rates of treatment-resistant conditions and suicide remain elevated.

From a regulatory and legal perspective, several implications emerge:

• Increased use of expedited regulatory pathways for emerging therapies
• Expansion of access mechanisms outside traditional approval frameworks
• Greater coordination between FDA and DEA on controlled substance oversight
• Growing role of federal and state investment in early-stage research

For pharmaceutical developers, the policy may create new opportunities to advance psychedelic drug candidates through regulatory pathways, while also introducing complexity related to compliance, evidence generation, and post-approval controls.

For providers and health systems, potential future access to these therapies will likely depend on evolving clinical guidelines, reimbursement frameworks, and regulatory safeguards.

Looking Ahead

While the executive order outlines a framework for accelerating development and access, its practical impact will depend on how federal agencies implement the directives, including the establishment of clear regulatory pathways and safeguards.

As interest in psychedelic therapies continues to grow, stakeholders across the life sciences and health care sectors will be closely monitoring how these policy changes influence clinical development, regulatory review, and eventual integration into standard care.

Reference

Fact sheet: President Donald J. Trump is accelerating medical treatments for serious mental illness. whitehouse.gov. Fact sheet. Published April 18, 2026. Accessed April 20, 2026. https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-is-accelerating-medical-treatments-for-serious-mental-illness/